Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Targeted Screening for Taenia Solium Tapeworms

This study has been completed.
Sponsor:
Collaborators:
Universidad Nacional Mayor de San Marcos
Information provided by (Responsible Party):
Seth E O'Neal, MD MPH, Oregon Health and Science University
ClinicalTrials.gov Identifier:
NCT01296958
First received: February 15, 2011
Last updated: October 22, 2014
Last verified: October 2014
  Purpose

The purpose of this study is to determine whether screening and treatment of tapeworm carriers can decrease community transmission of Taenia solium parasitic infection.


Condition Intervention
Taenia Solium Taeniasis
Drug: Niclosamide
Behavioral: Community education campaign

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Screening
Official Title: Targeted Screening for Taenia Solium Tapeworms

Resource links provided by NLM:


Further study details as provided by Oregon Health and Science University:

Primary Outcome Measures:
  • Porcine seroprevalence [ Time Frame: Every 4 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Intestinal tapeworm prevalence [ Time Frame: 16 months ] [ Designated as safety issue: No ]

Enrollment: 1811
Study Start Date: May 2011
Study Completion Date: January 2013
Primary Completion Date: January 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Targeted screening
Screening for intestinal tapeworm carrier followed by treatment with niclosamide as indicated.
Drug: Niclosamide
Single oral dose of niclosamide determined by weight (dose: 11 to 34kg receive 1 gram, 35 to 50kg receive 1.5 grams, over 50kg receive 2 grams)
Active Comparator: Education
Community education about Taenia solium prevention.
Behavioral: Community education campaign
Education about prevention of Taenia solium infection provided in a single short (20 minute) interaction with the participant. Education was verbal with visual aids.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • All community members are eligible

Exclusion Criteria:

  • Inability to provide informed consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01296958

Locations
Peru
San Marcos University
Lima, Peru
Sponsors and Collaborators
Oregon Health and Science University
Universidad Nacional Mayor de San Marcos
Investigators
Principal Investigator: Seth E ONeal, MD MPH Oregon Health and Science University
Principal Investigator: Armando Gonzalez, DVM PhD San Marcos University School of Veterinary Medicine
  More Information

No publications provided

Responsible Party: Seth E O'Neal, MD MPH, Assistant professor, Oregon Health and Science University
ClinicalTrials.gov Identifier: NCT01296958     History of Changes
Other Study ID Numbers: 1R21NS069275-01, 1R21NS069275-01
Study First Received: February 15, 2011
Last Updated: October 22, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by Oregon Health and Science University:
Taenia solium
cysticercosis
neurocysticercosis

Additional relevant MeSH terms:
Taeniasis
Cestode Infections
Helminthiasis
Parasitic Diseases
Niclosamide
Anthelmintics
Anti-Infective Agents
Anticestodal Agents
Antinematodal Agents
Antiparasitic Agents
Antiplatyhelmintic Agents
Pharmacologic Actions
Therapeutic Uses

ClinicalTrials.gov processed this record on November 25, 2014